STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans
Belgium drugmaker Argenx said Tuesday that its antibody medicine failed to achieve the goals of…
Category: drug development
How to spot when drug companies spin clinical trial results
Investors, analysts, doctors, and even patients face an avalanche of news from biotech companies about…
A new algorithm unveils CRISPR ‘treasure trove’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market
LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with…
Medtronic isn’t afraid of Wegovy’s potential to disrupt
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck cough drug doesn’t pass panel scrutiny
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The return of biotech’s “bump factor” amid an economic downturn
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle
Have you ever seen a mouse with a set of muscles more appropriate for a…
.jpg)
Key questions (and answers) about the historic approval of a CRISPR-based medicine
History just happened. For the first time, a regulator has cleared a treatment using CRISPR,…
STAT+: U.K. approves world’s first CRISPR-based medicine, giving greenlight to therapy for sickle cell, thalassemia
LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both…
The apparently strong correlation between biotech stocks and the price of eggs, explained
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novo Nordisk has its sights on becoming a major player in heart disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation
PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster…
.jpg)
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in…
The first vaccine for the increasingly prevalent chikungunya virus is here
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity
LONDON — Two days after similar decisions in the U.S. and U.K., regulators in Europe…
STAT+: Sanofi CEO defends company’s move to abandon profit guidance and boost research
LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon…
Your morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug
SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an…
XBI biotech index rises, giving investors a shred of hope
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Shrinking COVID vaccine sales has Moderna course-correcting
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Gene editing has had a big week in the spotlight. Here’s what’s going on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: DeepMind touts AlphaFold’s new skills as protein-folding AI models face off
On Tuesday, Google DeepMind and Isomorphic Labs announced a significant progress update on the next…
Sarepta’s disappointing data put the FDA in a difficult spot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Your Monday morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Regeneron gene therapy improves hearing in child
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The XBI biotech index hit its lowest point since 2018. No one knows what comes next.
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments
MADRID — If you had to pinpoint one subject that stood out at this year’s…
Why AstraZeneca’s CEO is accusing British tabloids of ‘fake news’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Results on Novartis prostate cancer therapy could expand its use
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic…
STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions
MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs…
STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca
MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson…
Johnson & Johnson antiviral pill for dengue shows early efficacy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a…
STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus…
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…
STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a…
What if there’s no market for a CRISPR cure?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
As Pfizer slashes revenue projections, Moderna says it “remains comfortable”
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
Studies highlight risks of excluding people with obesity from drug trials
People with obesity often go underrepresented in drug development trials, a critical gap that researchers…
Candor on gene therapy, Abiomed is warned, & BTK success in MS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Cell and gene therapies could be a safer bet than other drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…